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Abstract
Aims/hypothesis Over 50 regions of the genome have been
associated with type 1 diabetes risk, mainly using large case/
control collections. In a recent genome-wide association
(GWA) study, 18 novel susceptibility loci were identified and
replicated, including replication evidence from 2,319 families.
Here, we, the Type 1Diabetes Genetics Consortium (T1DGC),
aimed to exclude the possibility that any of the 18 loci were
false-positives due to population stratification by significantly
increasing the statistical power of our family study.
Methods We genotyped the most disease-predicting single-
nucleotide polymorphisms at the 18 susceptibility loci in
3,108 families and used existing genotype data for 2,319
families from the original study, providing 7,013 parent–
child trios for analysis. We tested for association using the
transmission disequilibrium test.
Results Seventeen of the 18 susceptibility loci reached nomi-
nal levels of significance (p<0.05) in the expanded family
collection, with 14q24.1 just falling short (p00.055). When
we allowed for multiple testing, ten of the 17 nominally
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-012-2450-3) contains peer-reviewed but unedited
supplementary material, including a full list of members of the Type 1
Diabetes Genetics Consortium, which is available to authorised users.
J. D. Cooper (*) : J. M. M. Howson :D. Smyth :N. M. Walker :
H. Stevens : J. H. M. Yang : J. A. Todd
Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes
and Inflammation Laboratory, Department of Medical Genetics,
Cambridge Institute for Medical Research,
University of Cambridge, Addenbrooke’s Hospital,
Cambridge CB2 0YX, UK
e-mail: jason.cooper@cimr.cam.ac.uk
J.-X. She
Medical College of Georgia,
Center for Biotechnology and Genomic Medicine,
Augusta, GA, USA
G. S. Eisenbarth :M. Rewers
Barbara Davis Center for Childhood Diabetes,
University of Colorado Health Sciences Center,
Denver, CO, USA
B. Akolkar
Division of Diabetes, Endocrinology, and Metabolic Diseases,
The National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), National Institutes of Health,
Bethesda, MD, USA
P. Concannon
Department of Biochemistry and Molecular Genetics,
University of Virginia,
Charlottesville, VA, USA
P. Concannon : S. S. Rich
Center for Public Health Genomics, University of Virginia,
Charlottesville, VA, USA
H. A. Erlich
Roche Molecular Systems,
Pleasanton, CA, USA
C. Julier
Inserm UMR-S958, Faculté de Médecine Denis-Diderot,
Paris and Centre National de Génotypage,
Evry, France
C. Julier
Université Paris 7 Denis-Diderot,
Paris, France
Diabetologia (2012) 55:996–1000
DOI 10.1007/s00125-012-2450-3
significant loci reached the required level of significance (p<
2.8×10−3). All susceptibility loci had consistent direction of
effects with the original study.
Conclusions/interpretation The results for the novel GWA
study-identified loci are genuine and not due to population
stratification. The next step, namely correlation of the most
disease-associated genotypes with phenotypes, such as
RNA and protein expression analyses for the candidate
genes within or near each of the susceptibility regions, can
now proceed.
Keywords Families . Population stratification bias . Power .
Replication . Susceptibility . Type 1 diabetes
Abbreviations
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Introduction
The publication of the first type 1 diabetes locus found by a
genome-wide association (GWA) study in 2006 (IFIH1) [1]
heralded a new era in susceptibility locus discovery in this
common autoimmune disease. Over 50 susceptibility loci have
now been identified (www.t1dbase.org). Eighteen of these
were identified by Barrett et al. [2] in a GWA meta-analysis
of 7,514 cases and 9,045 controls (meta-analysis p<1×10−6)
and confirmed in 4,267 cases, 4,670 controls and 2,319 affect-
ed sib-pair families (providing 4,342 parent–child trios; repli-
cation p<0.01; discovery and replication p<5×10−8) [2].
However, in the family component of the replication samples,
eight of the confirmed 18 susceptibility loci failed to reach
nominal levels of significance (p<0.05; inferred from the
reported 95% confidence intervals for the relative risks and
assuming two-sided significance tests). Although replication
was based on the combined evidence from case/control and
family collections, and no evidence of population stratification
in the case/control collection had been found previously [2, 3],
family-based evidence, if possible, remains important in order
to demonstrate that these associations did not arise through
population stratification bias [4]. Such a bias can occur when a
single nucleotide polymorphism (SNP) differs in allele fre-
quency across subgroups of the population and risk of disease
differs between these subgroups.
Based on the number of case/control and parent–child
trio replication samples used in Barrett et al. [2], if we
assume that the parent–child trios equate to an equal number
of cases and controls, the power of the case/control and
family replication sets would have been similar and the
potential impact of winner’s curse (the upward bias of the
effect size of the initial finding) on replication would not
differ between the replication sample sets. However, in type
1 diabetes, the effects (as measured by relative risk) of non-
HLA loci tend to be smaller in affected sib-pair families
[2, 5], which are enriched for type 1 diabetes with a higher
frequency of high-risk HLA genotypes. Consequently, when
the family component of the replication samples used in
Barrett et al. [2] is considered in isolation, the 2,319 affected
sib-pair families are likely to have been underpowered (too
few samples analysed) to replicate the initial associations.
Therefore, in the present study, we genotyped the best
disease-predicting SNPs at the 18 susceptibility loci [2] in
an additional 3,108 families (providing 2,801 parent–child
trios to the analysis) from the Type 1 Diabetes Genetics
Consortium (T1DGC) and the Juvenile Diabetes Research
Foundation/Wellcome Trust Diabetes and Inflammation
Laboratory. The analyses of these additional families, com-
bined with the original 2,319 families [2], provided protection
from population stratification bias, and increased power to
provide further replication support for the associations of these
18 susceptibility loci [2].
Methods
Subjects After the additional genotyping of 3,108 families
(2,322 families of white European ancestry and providing at
least one parent–child trio; electronic supplementary material
[ESM] Table 1), we had a collection of 5,427 families
(including 2,319 families previously genotyped [2]). All
families were collected with appropriate informed consent.
We analysed 4,429 families of white European ancestry and
providing one or more parent–child trios (ESM Table 1).
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Genotyping The best disease-predicting SNPs at the 18
susceptibility loci [2] were genotyped in the additional
family samples using the TaqMan 5′ nuclease assay (Applied
Biosystems,Warrington, UK) according to the manufacturer’s
protocol. Genotyping was performed blind to disease status
and double scored to minimise error. Genotype frequencies
were tested for deviation from Hardy–Weinberg equilibrium
(HWE), and genotype checks were conducted for SNPs that
deviated from HWE. We note that disease association can
result in deviation from HWE in affected offspring and parents
of affected offspring, who are not representative of the general
population. The same genotyping technology and protocols
had been applied in Barrett et al. [2] for the replication samples.
Statistical analysis All statistical analyses were performed
in either Stata (www.stata.com) or R (www.r-project.org). In
R, we used the snpStats package available from the Bio-
conductor project (www.bioconductor.org), and, in Stata, we
used some additional routines available from www-gene.
cimr.cam.ac.uk/clayton/software.
The family-based power to replicate the 18 type 1 diabetes
susceptibility loci [2] is reported in ESM Table 2. Based on the
odds ratios from the case/control component of the replication
samples in Barrett et al. [2], which are not subject to winner’s
curse, the expanded family collection is well powered, except
for 17q21.2/CCR7 (53.4% power at α00.05; 17.2% power at
α02.8×10−3, which corresponds to the Bonferroni adjustment
of the 0.05 significance level for the 18 independent tests; ESM
Table 2).We have greater than 90% power atα00.05 for 17/18
loci, and greater than 80% power atα02.8×10−3 for 14/18 loci
(17/18 have greater than 60% power at α02.8×10−3).
The best disease-predicting SNPs at the 18 susceptibility
loci were analysed using the transmission disequilibrium test,
except for the chromosome X locus, rs2664170 Xq28/GAB3,
which was analysed using the method proposed by Clayton
[6]. As we were attempting to replicate the associations
reported in the case/control component of the replication sam-
ples analysed in Barrett et al. [2], we performed one-sided
significance tests. We tested for population heterogeneity in
SNP genotype frequencies across unaffected parents using
Kruskal-Wallis one-way analysis of variance. We tested for
population heterogeneity in disease association, after generat-
ing pseudo-controls [7], by testing the addition of the geno-
type–population interaction term to the conditional logistic
regressionmodel of disease status on genotype and population.
Parent-of-origin and imprinting effects were tested using the
Wallace et al. extension of the Weinberg method [8, 9].
Results
As no p values have been reported previously for the 18
novel susceptibility loci in the family component of the
replication samples [2], we reanalysed the original data.
We excluded 312 families because of either non-white Eu-
ropean ancestry based on updated sample information or not
providing at least one parent–child trio. Seven of the 18 loci
failed to reach p<0.05 in these 2,107 families (providing
4,212 parent–child trios; Table 1). In other words, 11 of the
18 loci reach at least nominal levels of significance. If we
applied a Bonferroni adjustment for the 18 independent
tests, 15 loci failed to reach p<2.8×10−3.
The inclusion of the additional 2,322 families (providing
2,801 trios; 786 families excluded) increased the number of
susceptibility loci replicated at p<0.05 from 11 to 17 of the
18 loci. Only ZFP36L1, C14orf181/14q24.1 (p00.055)
failed to reach p<0.05 (Table 1). The number of suscepti-
bility loci replicated at p<2.8×10−3 increased from three to
ten (Table 1). Importantly, all of the susceptibility loci had
consistent direction of effects with the case/control and family
replication samples reported in Barrett et al. [2], and there was
no evidence of heterogeneity in the disease associations across
family collections, despite there being significant SNP geno-
type frequency differences (ESM Table 3). The difference in
SNP genotype frequencies across family collections was not
surprising given that Europe is a large and diverse collection
of countries. For example, we have a large number of families
from Finland, a genetically isolated population, which exhib-
its many and large differences in common SNP allele
frequencies.
We tested the 17 autosomal loci for parent-of-origin and
imprinting effects; only COBL/7p12.1 showed any evidence
of biased maternal transmission, p01.1×10−3 (ESM Table 4).
However, this needs to be replicated in an independent
dataset.
Discussion
In the expanded family collection, only one of the previously
confirmed susceptibility loci failed to reach nominal levels of
significance, ZFP36L1, C14orf181/14q24.1, as the p value
was just above 0.05. All of the susceptibility loci had consis-
tent direction of effects with the case/control component of the
replication samples reported inBarrett et al. [2] (ESMTable 5),
and even with our over-conservative threshold for multiple
testing, given the very strong prior information that these were
true effects [2], ten loci remained significant after the adjust-
ment for multiple testing. This study clearly demonstrates
that additional replication families were required for the 18
susceptibility loci to reach nominal levels of significance and
consequently that the previously reported associations (dis-
covery and replication p<5×10−8) with odds ratios often less
than 1.15 ([2]; ESM Table 5) did not arise through population
stratification bias, thereby further validating the case/control
collection (results).
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After unequivocal replication of type 1 diabetes loci, the
next steps involve dense SNP mapping in even larger sample
sets and experiments analysing genotype–phenotype associa-
tions. For example, studying correlations between type 1
diabetes SNP risk alleles and haplotypes and expression of
genes at the RNA and protein levels [10] can identify which
genes in the associated regions are more likely to be causal.
Consequently, genes with both positional and functional evi-
dence for a role in disease aetiology can reveal the pathways
and early precursors or biomarkers underlying the pathogen-
esis of type 1 diabetes.
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